Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:ImmunotherapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Oct 2013

Description:

Patients:
This study involved 39 metastatic uveal melanoma patients with a median age of 61 years, 59% of whom were male.

Treatment:
Patients were treated with the immune therapy agent ipilimumab, which is an antibody to the CTLA-4 protein and enhances the immune response against cancer cells.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 colitis (inflammation of the colon) and liver and pancreatic toxicities.

Results:
The median overall survival was 9.6 months.

Support:
Some of the authors have received funding from Bristol Myers Squibb (makers of ipilimumab).

Correspondence: Dr. Richard D. Carvajal; email: [email protected]



Back